Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
Women diagnosed with early stage ovarian cancer may be considered for adjuvant therapy. Intraperitoneal chromic phosphate (P-32) is commonly used in these patients with few complications. A woman found to have early stage ovarian cancer was given intraperitoneal P-32 in the presence of a lingering pelvic infection, which is usually not mentioned as a contraindication to its use. Radiation damage to the small bowel and cecum developed as did damage to the ureter and bladder, which then required surgery.
Department of Obstetrics and Gynecology, George Washington University, Washington, DC 20037.
L
L
McGowan
D000328:Adult; D017608:Chromium Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000075202:Contraindications; D018291:Cystadenoma, Mucinous / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007322:Instillation, Drug; D010051:Ovarian Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000601:surgery; D000292:Pelvic Inflammatory Disease / Q000150:complications*; D010529:Peritoneal Cavity; D010710:Phosphates / Q000009:adverse effects* / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D011832:Radiation Injuries / Q000209:etiology*; D018714:Radiotherapy, Adjuvant
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; C509369:chromic phosphate